124 results
Page 6 of 7
6-K
m3c72wo7
20 Nov 18
Current report (foreign)
7:00am
6-K
EX-99.1
98p1ha7w
16 Nov 18
Current report (foreign)
8:46am
6-K
EX-99.1
3uzgx0w chb
23 Oct 18
Newly Granted European Composition of Matter Patent Extends Exclusive Protection for VBL Therapeutics’ Lead Drug Candidate VB-111 until October 2033
8:16am
6-K
t8ush814 fc70f8hwf
16 Aug 18
Current report (foreign)
7:00am
424B5
myb8ky02 etm53c
27 Jun 18
Prospectus supplement for primary offering
9:30am
6-K
EX-99.1
rpfxihiy7 nhlwke
27 Jun 18
VBL Therapeutics Announces $15.5 Million Registered Direct Offering Priced At-the-Market
9:29am
6-K
EX-1.1
50dz9g0sp
27 Jun 18
VBL Therapeutics Announces $15.5 Million Registered Direct Offering Priced At-the-Market
9:29am
6-K
EX-4.1
n7ncit oxsytghe
27 Jun 18
VBL Therapeutics Announces $15.5 Million Registered Direct Offering Priced At-the-Market
9:29am
6-K
p60vns1dcsa6
17 May 18
Current report (foreign)
7:00am
6-K
EX-99.1
2s8zp4degd
23 Oct 17
VBL Therapeutics Celebrates Opening of its New Gene Therapy Manufacturing Plant and Company Headquarters
12:00am
6-K
EX-99.1
c3e5uboj obiw
20 Oct 17
VBL Therapeutics Announces Orphan Drug Designation for VB-111 In Europe
12:00am
20-F/A
EX-4.3
suu7y1
11 Oct 17
Annual report (foreign) (amended)
12:00am
20-F
tbbpovnfvq nm0d8
25 Mar 15
Annual report (foreign)
12:00am
6-K
itd5jkys1
22 Dec 14
Current report (foreign)
12:00am
424B4
7jpt e9n5byddqjv
2 Oct 14
Prospectus supplement with pricing info
12:00am
FWP
npf3xb i7g
30 Sep 14
Free writing prospectus
12:00am